Advanced Micro Devices rallies after the chip maker unveils a multiyear deal to supply computing power to Meta Platforms.
Life science incubator part of UC Berkeley's wider ecosystem, which has consistently ranked the number one university ...
Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...
This cancer drug has been touched by four companies over the past four years. Now it could help some of the sickest of the sick prostate cancer patients.
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for the “Madison Large Cap Fund”. A copy of the letter can be downloaded here.
Galapagos took a 228 million euro ($269 million) hit last year as it began to close its cell therapy business, but the Belgian biopharma is confident it can stabilize its finances by the end of the ...
Chinese biotechs are licensing assets to Western companies at record rates. Boston attorneys are racing to capture the dealmaking.
The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment ...
O]ur companies have until June of 2028 to get there. That should not be a sigh of relief. That should be a, oh my gosh, we've ...
Dr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at ...
Vir Biotechnology and Astellas entered a license agreement to co-develop and commercialize Vir's prostate cancer treatment. The agreement is for VIR-5500, a dual-masked T-cell engager targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results